BioCentury
ARTICLE | Clinical News

Lixisenatide/insulin glargine: Additional Phase III data

July 25, 2016 7:00 AM UTC

Additional data from the open-label, international Phase III LixiLan-L trial in 736 Type II diabetics inadequately controlled on basal insulin with or without 1-2 oral anti-diabetic drugs showed that once-daily subcutaneous iGlarLixi reduced mean HbA1c from baseline to week 30, the primary endpoint, by 1.1% vs. 0.6% for once-daily subcutaneous Lantus insulin glargine (p<0.0001). Additionally, a significantly greater proportion of patients receiving iGlarLixi achieved an HbA1c of <7% vs. Lantus (55% vs. 30%, p<0.0001). iGlarLixi also significantly reduced mean body weight by 0.7 kg vs. a 0.7 kg increase for Lantus (p<0.0001). Patients who were taking metformin at baseline continued their metformin treatment throughout the trial. Data were presented at the American Diabetes Association meeting in New Orleans. Sanofi previously reported that iGlarLixi met the primary endpoint (see BioCentury, Sept. 21, 2015). ...